Chemical Structure : CX-5461
CAS No.: 1138549-36-6
货号: PC-43493Not For Human Use, Lab Use Only.
Pidnarulex (CX-5461) is the first potent, selective, orally bioavailable inhibitor of RNA polymerase I, selectively inhibits rRNA synthesis in HCT-116 cells with IC50 of 142 nM, 200-fold selectivity over Pol II.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | ¥1980 | In stock | |
50 mg | ¥4980 | In stock | |
100 mg | ¥7280 | In stock | |
200 mg | Get quote | ||
1 g | Get quote |
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Pidnarulex (CX-5461) is the first potent, selective, orally bioavailable inhibitor of RNA polymerase I, selectively inhibits rRNA synthesis in HCT-116 cells with IC50 of 142 nM, 200-fold selectivity over Pol II.
Pidnarulex (CX-5461) inhibits the initiation stage of rRNA synthesis and induces both senescence and autophagy, but not apoptosis, through a p53-independent process in solid tumor cell lines.
Pidnarulex (CX-5461) demonstrates in vivo antitumor activity against human solid tumors in murine xenograft models.
分子量 | ||
分子式 | C27H27N7O2S | |
外观性状 | Solid | |
储存条件 |
|
|
Solubility |
DMSO: < 5.3 mg/mL |
|
Chemical Name/SMILES |
5H-Benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo- |
1. Haddach M, et al. ACS Med Chem Lett. 2012 May 8;3(7):602-6.
2. Drygin D, et al. Cancer Res. 2011 Feb 15;71(4):1418-30.
3. Bywater MJ, et al. Cancer Cell. 2012 Jul 10;22(1):51-65.
4. Achiron A, et al. J Neuroimmunol. 2013 Oct 15;263(1-2):91-7.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright